Business
Results Update
Results Update.
About this update from Physiomics Plc
[{"type":"text","content":"\n \nRNS Number : 1203E Physiomics PLC 01 April 2011 \n \n\nPhysiomics plc\n(\"Physiomics\" or \"the Company\")\n \nResults Update - Virtual Tumour shows improved drug schedule in cancer model\n \nPhysiomics (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that positive results have been generated in a pre-clinical in-vivo study into breast cancer based on the Company's \"Virtual Tumour\" model predictions. The directors believe these results provide further validation as to the predictive capability of the Company's technology.\n \nIn this study, Physiomics' \"Virtual Tumour\" model enabled the Company to design innovative combination regimens for the anti-cancer drugs docetaxel and gemcitabine. Three new schedules were tested experimentally in a breast cancer pre-clinical in-vivo model and Physiomics' predictions were substantiated. In the three cases, the doses were the same, but we adjusted the timing of the administration of the dose based on the \"Virtual Tumour\" simulation. The best schedule showed a 74% tumour growth inhibition compared to the untreated control group. This was 50% more efficient than the original schedule, achieved simply by adjusting the timing of administration. Furthermore the greater efficacy was achieved without increasing the toxicity.\n \nThe original schedule tested in this study is representative of the common practise in the clinic that is to give the two drugs to the patient at the same visit. Physiomics' modelling approach has shown that increasing the time interval between administrations of the two drugs has the potential to increase the clinical outcome, with no detectable increase in toxicity. The directors believe that this is the first time that this outcome has been reported for this drug combination in an in vivo pre-clinical study.\n \nThe Virtual Tumour platform is used to design optimal combination chemotherapy regimens. Thousands of simulations can be performed in silico if necessary to find the best treatment regime and save customers time and money.\n \nDr Christophe Chassagnole, COO at Physiomics, will present these new results at the AACR 102nd Annual Meeting 2011, taking place in the Orange County Convention Center, Orlando, Florida on 2-6 April 2011. The abstract (\"Modeling...